Cinemark
CNK
$39.61
-0.78%
Cinemark Holdings, Inc. is one of the largest motion picture exhibitors in the world, operating a geographically diverse network of multiplex theatres across the United States and Latin America that generates revenue primarily from box office receipts and high-margin concession sales, supplemented by screen advertising, screen rentals, and ancillary streams such as vendor promotions and studio trailer placements. Unlike heavily leveraged peers such as AMC, Cinemark is distinguished by a conservatively managed balance sheet, a premium-format and recliner-heavy theatre footprint, and a growing international presence that gives it a reputation as the most financially disciplined operator in the exhibition industry. The current investor narrative centers on the post-pandemic theatrical recovery, a strong 2026 box-office slate, and the company's aggressive capital-return posture, highlighted by a $300 million buyback program and new institutional buying even after a sharp drawdown earlier in the year. Attention is also focused on whether Cinemark can convert industry consolidation and competitor distress into durable market-share gains while sustaining its EBITDA momentum and margin expansion.…
CNK
Cinemark
$39.61
Related headlines
Investment Opinion: Should I buy CNK Today?
Rating: Hold (with a constructive bias). The core thesis is that Cinemark is the most financially disciplined exhibitor, trading at a reasonable 14.23x forward PE with unanimous analyst 'buy' consensus and a $40.27 average target, but the stock's 63.54% YTD rally has already captured much of the recovery, leaving only +4.7% average upside and thin margin of safety at $38.48. The consensus recommendation mean of 2.0 and 11-analyst coverage anchor a positive but not compelling risk/reward at current levels.
Supporting evidence is solid: forward EPS of $3.34 versus trailing $0.05 implies a dramatic earnings inflection, the forward PE of 14.23x is 28% below the trailing 19.69x, ROE of 34.11% and operating margin of 10.97% demonstrate operational quality, and price-to-cash-flow of 6.78x with EV/EBITDA of 11.79x confirms robust cash generation. The 1.45% dividend yield is covered by a 28.15% payout ratio, and the $300 million buyback plus new institutional buying signal management confidence. Relative strength of +51.61 points YTD versus SPY confirms the market is rewarding this discipline.
The biggest risks that could invalidate the thesis are: (1) forward EPS of $3.34 failing to materialize, which would make the trailing 19.69x multiple look expensive; (2) leverage of 9.34x debt-to-equity and a 0.71 current ratio limiting flexibility if box-office trends soften; and (3) valuation compression after the stock reached ~96.5% of its 52-week range. This Hold would upgrade to Buy if the stock pulls back toward the $34–$35 support zone (near the analyst low target) or if Q3 earnings confirm EPS tracking toward $3.34 with margin expansion; it would downgrade to Sell if revenue growth stalls, forward EPS estimates are cut below $3.19, or the stock breaks below $35 on rising volume. Valuation verdict: fairly valued to slightly undervalued on forward earnings, but no longer cheap after the rally — the stock is priced for a successful recovery, not for distress.
Sign up to view all
CNK 12-Month Price Forecast
The forward-looking view is balanced: Cinemark's 14.23x forward PE and unanimous 'buy' consensus support a constructive stance, but the 63.54% YTD rally has already priced in much of the recovery, leaving only +4.7% average upside and a thin margin of safety at $38.48. The base case (55% probability) assumes EPS lands near $3.34 and the stock consolidates toward $40, while the bull case (25%) requires a breakout above $39.79 toward $47 and the bear case (20%) reflects a retrace toward $34 or lower if estimates are cut. I would upgrade to bullish if Q3 earnings confirm EPS tracking toward $3.50 with margin expansion and the stock breaks $39.79 on volume; I would downgrade to bearish if forward EPS estimates fall below $3.19 or the stock breaks below $35 support. Confidence is medium because the trailing-to-forward EPS gap is the single largest uncertainty and cannot be fully validated without quarterly filings.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cinemark's 12-month outlook, with a consensus price target around $40.73 and implied upside of +2.8% versus the current price.
Average Target
$40.73
0 analysts
Implied Upside
+2.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$34 - $47
Analyst target range
Cinemark is covered by 11 analysts with a consensus recommendation of "buy" (mean rating of 2.0 on a scale where lower is more bullish) and an average target price of $40.27. Against the current price of $38.48, that implies roughly +4.7% upside to the consensus target — a modest but positive signal that suggests the stock is fairly valued to slightly undervalued after its sharp run. The bullish consensus is notable given the stock has already rallied 45.21% over the past year, indicating analysts see further room rather than calling a top.
The target range spans $34.00 to $47.00, a spread of about 38% around the average, which signals meaningful disagreement about the company's trajectory. The high target of $47.00 (roughly +22% above the current price) likely assumes continued box-office recovery, margin expansion, and multiple re-rating toward the upper end of historical ranges, while the low target of $34.00 (about -11.6% downside) prices in margin compression, a weaker film slate, or leverage-related risk. The wide spread, combined with the elevated short ratio of 3.73, indicates genuine two-sided debate; with estimated EPS averaging $3.34 and revenue near $4.29 billion, the consensus leans constructive but the dispersion argues for position sizing discipline and attention to upcoming earnings as the key catalyst.
Bulls vs Bears: CNK Investment Factors
The bull case currently has stronger evidence: CNK's 51.61-point YTD relative strength versus SPY, 34.11% ROE, 6.78x price-to-cash-flow, and unanimous analyst 'buy' consensus with a $40.27 average target all point to a disciplined operator in a powerful uptrend. However, the bear case is not weak — debt-to-equity of 9.34, a 0.71 current ratio, and a 4.44% net margin mean the entire thesis rests on forward EPS of $3.34 materializing. The single most important tension is whether the forward earnings inflection is real: if realized EPS tracks consensus, the 14.23x forward PE is cheap and the stock can break $39.79 toward $47; if it disappoints, the trailing 19.69x multiple on $0.05 EPS looks expensive and the stock could retrace toward the $34 low target. Near-term momentum and analyst sentiment favor the bulls, but the margin of safety at $38.48 is thin, making upcoming earnings the decisive catalyst.
Bullish
- Powerful relative strength leadership: CNK is up 63.54% YTD versus SPY's 11.93%, a 51.61-point relative strength spread, and 45.21% over one year versus 15.53% for SPY. The 1-month relative strength of +11.86 points shows outperformance is widening, not fading, confirming genuine leadership rather than a beta-driven rally (beta 1.027).
- Forward earnings inflection priced in: Forward EPS of $3.34 versus trailing EPS of $0.05 implies a dramatic profitability step-up, and the forward PE of 14.23x versus trailing 19.69x reflects 28% multiple compression as earnings normalize. Analyst revenue estimates of ~$4.29 billion and EPS range of $3.19–$3.50 suggest consensus expects a durable recovery.
- Strong cash generation and capital returns: Price-to-cash-flow of 6.78x and EV/EBITDA of 11.79x indicate robust operating cash flow relative to market value, while the 1.45% dividend yield is covered by a conservative 28.15% payout ratio. The $300 million buyback program and new institutional buying signal confidence in the cash flow outlook.
- Exceptional ROE and operating margin: ROE of 34.11% and operating margin of 10.97% demonstrate efficient capital use and cost discipline for a capital-intensive exhibitor. Gross margin of 18.55% reflects a favorable concession mix, and ROA of 5.97% is respectable given the lease-heavy asset base.
Bearish
- Extreme leverage and tight liquidity: Debt-to-equity of 9.34 is extremely elevated, and a current ratio of 0.71 means current liabilities exceed current assets, signaling tight near-term liquidity. This leaves CNK vulnerable to refinancing conditions and any box-office softness, even if it is the most disciplined exhibitor.
- Thin net margin and earnings volatility: Net margin of just 4.44% reflects the burden of interest and depreciation, and trailing EPS of $0.05 makes the trailing PE of 19.69x look expensive if forward estimates slip. The 65x gap between trailing and forward EPS is the single biggest fundamental uncertainty in the dataset.
- Overextended near 52-week high: At $38.48, the stock sits at ~96.5% of its 52-week range ($21.60–$39.79), just 3.4% below resistance, after a 63.54% YTD run. The max drawdown of -27.89% over the period underscores mean-reversion risk, and a failure at $39.79 could trigger profit-taking toward the $34–$35 support zone.
- Wide analyst target dispersion: Targets span $34.00 to $47.00, a ~38% spread around the $40.27 average, signaling genuine two-sided debate. The low target of $34.00 implies -11.6% downside and prices in margin compression or a weaker film slate, while the modest +4.7% average upside offers limited margin of safety.
CNK Technical Analysis
Cinemark is in a powerful, sustained uptrend, with the stock up 45.21% over the past year and an even more striking 63.54% year-to-date, dramatically outpacing the S&P 500's 15.53% and 11.93% respective gains. At a current price of $38.48, the stock sits at roughly 96.5% of its 52-week range of $21.60 to $39.79, positioning it just below its highs — a sign of strong momentum but also a zone where profit-taking and overextension risk rise. The 1-year relative strength of +29.68 percentage points versus SPY confirms this is a genuine leadership move rather than a beta-driven rally, given the stock's market-like beta of 1.027.
Short-term momentum is accelerating rather than fading: the stock is up 13.08% over the past month and 26.50% over three months, with the 1-month relative strength of +11.86 points versus SPY showing the outperformance is widening, not narrowing. This is a bullish confirmation pattern — the 1-month gain (13.08%) is roughly half the 3-month gain (26.50%), indicating steady rather than parabolic accumulation, and the 6-month change of 28.22% shows the move has been built over multiple quarters. The most recent session was essentially flat (down 0.10% from a $38.52 previous close), suggesting consolidation near resistance rather than distribution, though the elevated short ratio of 3.73 days-to-cover indicates a meaningful short base that could fuel further squeezes on a breakout.
Key technical levels are well defined: resistance sits at the 52-week high of $39.79, just 3.4% above the current $38.48, while support anchors near the 52-week low of $21.60, with intermediate support likely around the $34-$35 zone where the stock consolidated in September. A decisive breakout above $39.79 would signal a fresh leg higher and likely trigger short covering, whereas a failure and breakdown below $35 would suggest the 45.21% one-year advance is due for mean reversion. With a beta of 1.027 the stock carries roughly market-level volatility, but the max drawdown of -27.89% over the period underscores that this is still a cyclical, sentiment-sensitive name requiring disciplined position sizing and stop placement.
Beta
1.03
1.03x market volatility
Max Drawdown
-27.9%
Largest decline past year
52-Week Range
$22-$41
Price range past year
Annual Return
+50.6%
Cumulative gain past year
| Period | CNK Return | S&P 500 |
|---|---|---|
| 1m | +10.4% | -1.2% |
| 3m | +21.1% | +3.4% |
| 6m | +39.1% | +7.0% |
| 1y | +50.6% | +14.4% |
| ytd | +68.3% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CNK Fundamental Analysis
Revenue trajectory data is not available in the provided quarterly financials, income statement, or segment disclosures, so a multi-quarter growth analysis cannot be constructed from the inputs. However, the analyst consensus revenue estimate of approximately $4.29 billion (range $4.14 billion to $4.45 billion) implies a business operating at meaningful scale, and the forward EPS estimate of $3.34 versus trailing EPS of just $0.05 signals the market expects a dramatic earnings inflection — a roughly 65x step-up in profitability that reflects either depressed trailing results or a major recovery in the forward outlook. This gap between trailing and forward earnings is the single most important fundamental signal in the dataset and warrants scrutiny of the underlying quarterly filings.
Profitability metrics show a company that is solidly profitable but with thin net margins characteristic of exhibition economics: net margin stands at 4.44%, operating margin at 10.97%, and gross margin at 18.55%. The operating margin of nearly 11% is healthy for a theatre operator and suggests disciplined cost control and a favorable concession mix, while the 4.44% net margin reflects the burden of interest expense and depreciation inherent to a capital-intensive, lease-heavy model. Return on equity of 34.11% is exceptionally strong and ROA of 5.97% is respectable, indicating efficient use of capital despite the thin net margin — though the high ROE is partly a function of leverage rather than pure operational excellence.
Balance sheet and cash flow analysis reveals the key risk: debt-to-equity of 9.34 is extremely elevated, and a current ratio of 0.71 means current liabilities exceed current assets, signaling tight near-term liquidity that is typical of exhibitors but still a vulnerability if box-office trends soften. On the positive side, the price-to-cash-flow ratio of 6.78 suggests the company generates robust operating cash flow relative to its market value, and the dividend yield of 1.45% with a conservative payout ratio of 28.15% indicates cash returns are well covered by earnings. The combination of high leverage, sub-1.0 current ratio, and strong cash generation means Cinemark funds growth largely internally but remains sensitive to refinancing conditions and any deterioration in free cash flow.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CNK Overvalued?
Because trailing net income is positive (EPS of $0.05), the PE ratio is the appropriate primary metric, and the trailing PE of 19.69x versus a forward PE of 14.23x is the central valuation story. The 28% compression from trailing to forward multiple implies the market is pricing in substantial earnings growth — consistent with the forward EPS estimate of $3.34 versus the trailing $0.05 — and the forward multiple of 14.23x is modest in absolute terms for a company with 34.11% ROE. The PEG ratio of -0.37 is not meaningful given the near-zero trailing earnings base and should be disregarded.
On peer comparison, the price-to-sales ratio of 0.86x and EV/sales of 2.05x are low in absolute terms, reflecting the capital-intensive, low-margin nature of exhibition; the EV/EBITDA of 11.79x is the more relevant peer metric and sits in a reasonable range for theatre operators, neither a clear premium nor a deep discount. The price-to-book ratio of 6.63x looks rich, but for an asset-light-on-equity, lease-heavy business, book value is a poor anchor. Without explicit industry-average multiples in the provided data, a precise premium/discount spread cannot be quantified, but the sub-1.0x sales multiple and 11.79x EV/EBITDA suggest the stock is not expensively valued relative to its cash-generation profile.
Historical ratio data is not available, so the current valuation cannot be benchmarked against Cinemark's own multi-year PE or PS band. Qualitatively, a forward PE of 14.23x combined with a 63.54% year-to-date rally suggests the market has already re-rated the stock meaningfully off its lows, and the current multiple likely sits in the upper half of its historical range — pricing in optimistic box-office and margin expectations rather than distress. Investors should treat the forward multiple as the key valuation anchor and watch whether realized earnings track the $3.34 consensus, since any shortfall would quickly make the trailing 19.69x look expensive.
PE
19.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are dominated by Cinemark's balance sheet: debt-to-equity of 9.34 is extremely elevated, and a current ratio of 0.71 means current liabilities exceed current assets, leaving little near-term liquidity buffer if box-office receipts soften. The 4.44% net margin is thin enough that a modest revenue decline could wipe out a large share of earnings, and trailing EPS of just $0.05 means the trailing PE of 19.69x is highly sensitive to any shortfall versus the $3.34 forward consensus. Revenue is concentrated in theatrical box office and concessions, so a weak film slate or a shift toward streaming windows would hit both the top line and the high-margin concession attach rate simultaneously. The 28.15% payout ratio and 1.45% yield are well covered, but the $300 million buyback competes with debt service for cash, and any deterioration in free cash flow would pressure both capital returns and refinancing flexibility.
Market and competitive risks center on valuation compression after a 63.54% YTD rally that has taken the stock to ~96.5% of its 52-week range. The forward PE of 14.23x is modest in absolute terms, but the stock has already re-rated meaningfully off its lows, and the +4.7% average analyst upside offers little cushion if multiples normalize. Beta of 1.027 means CNK offers no defensive offset to a broad market drawdown, and the elevated short ratio of 3.73 days-to-cover reflects genuine bearish positioning that could amplify volatility in either direction. Competitive dynamics are a double-edged sword: AMC's theatre optimization and record EBITDA (per September 2026 news) validate the industry recovery, but AMC's $200 million equity offering and dilution concerns (July 2026) highlight how fragile exhibitor balance sheets remain, and any competitor distress that forces asset sales or aggressive pricing could pressure Cinemark's market share and margins.
The worst-case scenario is a chain in which a disappointing film slate or a macro-driven consumer pullback causes Q3/Q4 box-office receipts to miss, forward EPS estimates of $3.34 are cut toward the $3.19 low end or below, and the market re-rates the stock on trailing earnings. In that scenario, the stock could retrace from $38.48 toward the analyst low target of $34.00 (-11.6%), and a deeper de-rating toward the September consolidation zone of $34–$35 or the 52-week low of $21.60 would imply losses of roughly -12% to -44%. The historical max drawdown of -27.89% over the period provides a realistic intermediate downside anchor, meaning an investor could lose roughly 28% from current levels in a full mean-reversion scenario before reaching the $21.60 low.
FAQ
The most severe risk is financial: debt-to-equity of 9.34 and a current ratio of 0.71 leave little liquidity buffer, and a 4.44% net margin means a modest revenue decline could wipe out a large share of earnings. Second is earnings-execution risk: trailing EPS of $0.05 versus a $3.34 forward estimate is a 65x gap, and if box-office receipts disappoint, the trailing 19.69x multiple would look expensive and estimates could be cut below the $3.19 low end. Third is valuation and momentum risk: the stock sits at ~96.5% of its 52-week range after a 63.54% YTD rally, with a -27.89% max drawdown and a $34.00 analyst low target implying -11.6% downside. Fourth is competitive and macro risk: beta of 1.027 offers no defensive offset, and AMC's theatre optimization and dilution moves could shift industry pricing and market share. Ranked by severity: financial leverage first, earnings execution second, valuation/momentum third, competitive/macro fourth.
The 12-month forecast has three scenarios: a base case (55% probability) of $38–$42 assuming EPS lands near the $3.34 consensus and the stock tracks toward the $40.27 average target; a bull case (25%) of $44–$47 requiring a breakout above $39.79, EPS toward $3.50, and margin expansion; and a bear case (20%) of $21.60–$34.00 if forward EPS is cut below $3.19 and the stock breaks the $34–$35 support zone. The base case is most likely because it requires only that consensus estimates be met, which the unanimous 'buy' rating and 11-analyst coverage suggest is the central expectation. The key assumption behind the base case is that the 2026 film slate supports revenue near $4.29 billion and operating margin near 10.97%, validating the 14.23x forward PE.
CNK appears fairly valued to slightly undervalued on forward earnings but no longer cheap after its rally. The forward PE of 14.23x is 28% below the trailing 19.69x, reflecting the market's expectation that EPS jumps from $0.05 to $3.34, and the price-to-sales of 0.86x and EV/EBITDA of 11.79x are modest in absolute terms for a cash-generative exhibitor. However, the 63.54% YTD rally means the stock has already re-rated meaningfully off its lows, and the +4.7% average analyst upside suggests the market is pricing in a successful recovery rather than distress. The price-to-book of 6.63x looks rich but is a poor anchor for a lease-heavy business, and the PEG ratio of -0.37 is not meaningful given the near-zero trailing earnings base. Net, the valuation implies the market expects the $3.34 forward EPS to be delivered — any shortfall would quickly make the trailing 19.69x look expensive.
From a risk/reward perspective, CNK is a reasonable but not compelling buy at $38.48: the 14.23x forward PE and unanimous 'buy' consensus with a $40.27 average target imply only +4.7% upside, while the low target of $34.00 implies -11.6% downside and the 52-week low of $21.60 implies roughly -44%. The bull case rests on forward EPS of $3.34 materializing against trailing EPS of just $0.05, a 65x step-up that is the single biggest uncertainty in the thesis. Balance-sheet discipline (34.11% ROE, 6.78x price-to-cash-flow, covered 1.45% dividend) supports the quality case, but debt-to-equity of 9.34 and a 0.71 current ratio limit the margin of safety. It is a good buy for investors with a 12–18 month horizon who want theatrical recovery exposure and are willing to add on pullbacks toward $34–$35; it is less attractive for those buying at the current ~96.5% of 52-week range without a catalyst.
CNK is better suited to a medium-to-long-term holding period of at least 12–18 months than to short-term trading. The growth stage is a post-pandemic recovery with a forward EPS inflection from $0.05 to $3.34, which requires time to be validated across multiple quarters, and the 1.45% dividend with a 28.15% payout ratio provides modest income while waiting. Volatility is market-like (beta 1.027) but the -27.89% max drawdown and 3.73 short ratio mean short-term price action can be violent, making it a poor vehicle for traders without tight risk controls. Earnings visibility is moderate — the wide $34–$47 analyst target range reflects genuine uncertainty about the film slate and margin trajectory. A minimum 12–18 month holding period allows the forward earnings inflection to be proven and captures the base-case path toward $40–$42, while a shorter horizon risks being caught in a mean-reversion move toward $34.